Document:

Exhibit 10(q)

      Pharmos Corporation

        99 Wood Avenue South, Suite 311

      Iselin, NJ 08830

	 	 
	 	April 20, 2004

	 
	Mr. Robert W. Cook

    [Home Address]

      Dear Bob:

      This letter sets forth our entire agreement regarding your separation as the Executive Vice President and Chief Financial Officer of Pharmos Corporation (the “Company”), notwithstanding the provisions of your Employment Agreement dated as of April 2, 2001, as amended (the “Employment Agreement”). This letter supersedes the Employment Agreement, and to the extent there is any inconsistency between the terms of the Employment Agreement and this letter agreement, the terms hereof will govern. We have agreed as follows: 

      1.  Resignation.  The Company and you each acknowledge that you effectively gave us notice of your resignation on March 22, 2004. We have agreed that you will remain as an employee of the Company through April 22, 2004, at which time you will relinquish your duties as Executive Vice President and Chief Financial Officer of the Company. Thereafter, you will serve as a paid consultant to the Company through May 22, 2004, assisting management with transition matters and in general corporate finance and administrative matters (the period from the date hereof through May 22, 2004 is referred to as the “Paid Employment and Consultancy Period”). From April 23 through May 22, 2004, you will continue to be paid your current base rate of compensation. Although you may start employment with your new employer after April 22, you have agreed to be reasonably available to the Company by telephone and in person after that date through the end of the Paid Employment and Consultancy Period.

      2.  Payment of Benefits. During the Paid Employment and Consultancy Period, you will continue to receive all health benefits available to employees of the Company. Your eligibility for participation in the Company’s benefit plans will cease on May 23, 2004, except for your right to group medical coverage pursuant to COBRA.

      3.  Additional Payments. At the end of the Paid Employment and Consultancy Period, the Company will pay you the additional sum of $5,250, which represents approximately one-half of the agreed upon additional annual bonus payment payable to you in connection with your purchase of life insurance, as provided in the letter agreement dated as of October 8, 2003 between you and the Company, which letter agreement hereby is terminated and superseded. At such time the Company will also pay to you all as then accrued but unpaid vacation pay.

      4.  Unpaid Consultancy Period. From May 23 through December 31, 2004 (the “Termination Date”), you will serve as an unpaid consultant to advise the Corporation on general finance and administration matters, including compliance, corporate governance and corporate finance, and will be reasonably available by telephone, and if possible, to meet occasionally with members of the Corporation’s management on a limited basis.

    
	 

	

	
5.  Stock Options.  You will retain one hundred percent (100%) of your fully vested stock options issued to you by the Company prior to and until the Termination Date, but you shall not have any rights to any unvested stock options. Vesting will continue on your unvested stock options through and including
the Termination Date but will cease vesting on the date of your death if prior to the Termination
Date. All vested stock options must be exercised by you on or prior to March 31, 2005, in accordance
with the terms of the applicable stock option agreements, or in the event of your prior death, by
your personal representative or estate within the applicable exercise period provided in such stock
option agreements in the event of death (the “Option Exercise Termination Date”).

6.  Limitations on Sale of Stock. You agree that through the Option Exercise Termination Date, you will not sell more shares of the
Company’s common stock in any given calendar week, without the prior consent of the Company,
than the average daily trading volume of the Company’s stock, as determined from the previous
week’s average daily trading volume; provided, however, that if such average daily trading volume
is less than 40,000 shares, you may sell up to 40,000 shares and if such average daily trading volume
exceeds 100,000 shares, the maximum number of shares you can sell is 100,000. 

7.  No Other Payments or Benefits; Release. Other than the payments specifically set forth in this letter, you agree that the Company does not
owe you any further payments, compensation, remuneration, bonuses, incentive payments, benefits,
stock options, severance, or commissions of any kind whatsoever, including any obligations owed to
you under the Employment Agreement. You also hereby release the Company and its subsidiaries, as
well as each of their respective stockholders, agents, employees, officers and directors, of and
from any and all claims or liabilities that you have or may have, both known and unknown, arising
through the date of this letter, including any claims arising out of your employment with the Company
or the termination of your employment with the Company, but excluding the obligations of the Company
under this letter.

8.  Return of Property. Prior to April 22, 2004, you will return to the Company any and all files or other property of the
Company, including files, purchase orders, financial reports, projections, forecasts, balance sheets,
income statements, audited financial statements, total cost development budgets, actual or prospective
purchaser or customer lists, written proposals and studies, plans, drawings, specifications, reports
to creditors, books, accounts, reports to directors, minutes, resolutions, certificates, bank account
numbers, passwords, credit cards, computers, cellular or other telephones, beepers, keys, deeds,
contracts, office equipment and supplies, records, computer discs, etc. without retaining any copies
or extracts thereof.

9.  Confidentiality of this Agreement. You agree that this letter, and any and all matters concerning your employment with and separation
from the Company, will be regarded as privileged communications between the parties, and you will
not reveal, disseminate by publication of any sort, or release in any manner or means this letter
or any matters, factual or legal, concerning this letter or your separation to any other person or
entity, except as required by legal process (in which case, you agree to forthwith provide written
notice of said legal process below prior to the production of the requested information).

10.   Ongoing Obligations. 

(a)  With the exception of the duties and responsibilities set forth in this agreement, you
acknowledge and agree that you are relieved of all duties and responsibilities for the Company and
that you do not have the authority to bind the Company.

(b)  The Company and you each agree that neither party shall at any time engage in any form
of conduct, or make any statements or representations, that disparage or otherwise impair the reputation,
goodwill or commercial interests of each other, or the Company’s management, stockholders, subsidiaries,
parents, and/or other direct or indirect affiliates. 

	

2

	
(c)  You agree that until March 31, 2005, you will not solicit any employee, contractor or
consultant of the Company away from employment or retention by the Company, except that you may solicit
the services of a contractor or consultant if it would not affect or limit the services they either
currently are providing to the Company or are providing at the time of such solicitation. 

(d)  If requested, you will complete any certifications of financial results reasonably required
by the Company with respect to the fiscal quarter ended March 31, 2004, and you further confirm and
attest that you are not aware of any business or financial information which would be inconsistent
with the Company’s most recent filings made by it with the Securities and Exchange Commission.

11.  Nondisclosure of Confidential Information. You acknowledge and agree that the Confidential Information section as set forth in Section 10 of
the Employment Agreement is effective and shall remain in effect in accordance with its terms through
March 31, 2005.

12.  Indemnification against certain Third Party Claims; No Release by the Company; Cooperation. The Company will indemnify and hold you harmless for any third party claim asserted against you for
which you otherwise would have been covered by the Company’s officers’ and directors’
liability insurance had you remained an employee of the Company. This indemnification does not constitute
any release by the Company of any claims it might have against you directly for your acts or omissions
committed while under the employment of the Company, or any such acts or omissions which would not
be covered by the Company’s liability insurance. You will cooperate fully with the Company in
connection with any existing or future litigation involving the Company, its officers, directors,
employees or agents, whether administrative, civil or criminal in nature, in which and to the extent
the Company reasonably deems your cooperation necessary, and you will be reimbursed for your reasonable
out of pocket expenses in connection with such cooperation.

13.  Approval by Compensation Committee. You acknowledge that our agreements provided in this letter are subject to approval of the Compensation
Committee of the Company’s Board of Directors.

[Remainder of page intentionally omitted]

	

3

	
                 Please acknowledge your acceptance of the foregoing by signing and returning a copy of this letter
to me.

	 

	 	PHARMOS CORPORATION
	 	 	 	 
	 	 	 	 
	 	By:	/s/	 HAIM AVIV
	 	 	

	 	 	 	Haim Aviv 
	 	 	 	Chairman and Chief Executive Officer 

	 
	AGREED AND ACCEPTED:
	 
	 
	/s/  ROBERT W. COOK
	

	Robert W. Cook

	

4Exhibit 10(v)

AMENDMENT NO. 2 TO ASSET PURCHASE AGREEMENT

                 This Amendment No. 2 to Asset Purchase Agreement dated as of December 30, 2004 (“Amendment No.
2”) between Bausch & Lomb Incorporated, a New York corporation with its principal place
of business at One Bausch & Lomb Place, Rochester, NY 14604-2701 (“Buyer”) and Pharmos
Corporation, a Nevada corporation with its principal place of business at 99 Wood Avenue South, Suite
311, Iselin, NJ 08830 (“Seller”).

                 WHEREAS,
Buyer and Seller entered into the Asset Purchase Agreement dated as of October 9, 2001, as amended
by Amendment No. 1 to Asset Purchase Agreement dated as of December 28, 2001 (collectively the “Asset
Purchase Agreement”); and

                 WHEREAS, Buyer and Seller desire to amend the Asset Purchase Agreement to provide the final amount
of the First Contingent Payment and the final LE-T R&D Costs (each as defined in the Asset Purchase
Agreement).

                 NOW, THEREFORE, in consideration of the mutual agreements contained herein, and other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree
as follows:

                 1. Defined Terms. Unless otherwise indicated, capitalized terms used herein shall have the meanings
ascribed to them in the Asset Purchase Agreement.

                 2. Amendment of Asset Purchase Agreement. The parties hereby agree that the Asset Purchase Agreement
shall be amended to provide that:

	 

		(i)	Pursuant to Section 2.7.1 of the Asset Purchase Agreement, the First Contingent Payment shall equal
Twelve Million One Hundred Sixty Thousand Dollars ($12,160,000);
			 
		(ii)	Pursuant to Section 6.7.2 of the Asset Purchase Agreement, Buyer has provided Seller with the
final accounting of the LE-T R&D Costs owed by Seller in the amount of One Million Five Hundred
Thirty Two Thousand Five Hundred Twenty Eight Dollars ($1,532,528), which amount shall be credited
to Buyer against the First Contingent Payment at the time the First Contingent Payment is paid; and
			 
		(iii)	Seller and Buyer agree that at the payment date, Buyer will remit the sum of $1,337,600 to Dr. Nicholas
Boder, which represents 11% of the Section 2.7.1 of the Asset Purchase Agreement First Contingent
Payment. Seller will secure the Acknowledgement and Receipt (Exhibit 1) from Dr. Bodor and transmit
it to Buyer prior to Buyer releasing any funds.

	 
	
                 3. Other Asset Purchase Agreement Provisions. Except as otherwise expressly provided in this Amendment
No. 2, the provisions of the Asset Purchase Agreement remain in full force and effect.

	 

	

	

                 4. Other Actions Necessary. At the reasonable request of one of the parties hereto, the other party
shall execute any other documents or take any other reasonable actions necessary to effectuate this
Amendment No. 2.

                 5. Binding Effect. This Amendment No. 2 shall inure to the benefit of and shall be binding upon the
parties and their respective successors and assigns.

                 6. Amendments, Changes and Modifications. This Amendment No. 2 may not be amended, changed, modified,
altered or terminated without the prior written consent of all of the parties hereto.

                 7. Applicable Law. This Amendment No. 2 shall be governed exclusively by the applicable laws of the
State of New York without regard to its conflict of laws principles.

                 8. Execution of Counterparts. This Amendment No. 2 may be executed in several counterparts, each of
which shall be an original and all of which shall constitute but one and the same instrument.

                 IN WITNESS WHEREOF, the parties have executed this Amendment No. 2 to Asset Purchase Agreement as of
the day and year first above written.

	 

	 	BAUSCH & LOMB INCORPORATED
	 	 	 	 
	 	 	 	 
	 	By:	/s/	Stephen C.McCluski
	 	 	Name: Stephen C. Mc Cluski
	 	 	Title: Sr. VP & CFO
	 	 
	 	PHARMOS CORPORATION 
	 	 	 	 
	 	 	 	 
	 	By:	/s/	James A. Meer
	 	 	Name: James A. Meer
	 	 	Title:Vice President, CFO, Secretary &

    Treasurer

	

2

	
Exhibit 1 to Amendment No. 2 Asset Purchase Agreement

Pharmos Corporation

January 13, 2005

Dr. Nicholas Bodor

10101 Collins Avenue #4A

Bal Harbour, Fl 33154

Re: License Agreement 10/9/2001 among Dr. Bodor, Pharmos Corp and Bausch and Lomb

Dear Dr. Bodor:

Bausch and Lomb is preparing to make its First Contingent payment under its agreement with Pharmos
Corporation. This triggers a payment to you under Section 2c of the above referenced License Agreement
in the amount of $1,337,000, which is 11% of the First Contingent payment of $12,160,000.

Please acknowledge receipt of payment from Bausch and Lomb on behalf of Pharmos Corporation and the
amount due under the referenced agreement.

In addition, please sign and return the copy of this letter in the enclosed envelope to acknowledge
receipt of this letter.

Thank you,

Very truly yours,

James A. Meer

Vice President CFO, Secretary and Treasurer

Pharmos Corporation

Enclosure

	 	 	 
	_________________________	 	__________________
	Nicholas Bodor	 	Date

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00079-of-00352.parquet"}]]